Skin Cancer

Latest News


Neil Gross, MD, FACS, MD Anderson Cancer Center

Currently, there is no treatment approved for resectable cutaneous squamous cell carcinoma (cSCC), nor do we have biomarkers to predict treatment response, noted Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center

Neil Gross, MD, FACS, MD Anderson Cancer Center

Patients may be able to forgo radiation following use of cemiplimab to treat their resectable cutaneous squamous cell carcinoma (cSCC), as it is likely to demonstrate significant improvement in quality of life (QOL) for patients and enable less invasive surgeries, noted Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center.

Igor Puzanov, MD, Jacobs School of Medicine and Biomedical Sciences and Roswell Park Comprehensive Cancer Center

In this interview with The American Journal of Managed Care® (AJMC®), Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, discusses the state of treatment selection in the setting of resected advanced melanoma, why sequencing of therapies does not occur in the setting of adjuvant therapy, and best practices to keep in mind for patient education and managing their treatment-related toxicities.

Vernon Sondak MD

In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating patients with melanoma with BRAF mutations, including those whose disease has spread to the brain or other sites.